Immunomodulating agents
Review articleOpen access
Abstract:

Publisher SummaryImmunotherapeutic approach is increasingly being used in cancer treatment. This chapter discusses some speculations on the immunotherapy of allergic diseases. In spite of the considerable potential, the field of immunomodulating agents is progressing quite slowly. Interleukin-2 is a glycoprotein lymphokine produced by activated T-lymphocytes, which has been shown to play an important role in the immunological response. Administration of interleukin-2 may prove useful in the therapy of severe infectious diseases, particularly those developing in immunocompromised patients. Interleukin-2 has also been proposed as treatment for immunodeficiency. Intravenous administration of Staphylococcus aureus preparations may induce life-threatening cardiovascular and respiratory toxicity. Schizophyllan, a glucan extracted from the culture broth of Schizophyllum commune has been evaluated in association with tegafur for the treatment of resectable gastric cancer. An unexpectedly high rate of adverse reactions was reported among 15 patients with chronic lymphocytic leukemia who received 300 mg oral levamisole per week for four weeks; the most severe hematological complication was thrombopenia. Tiredness, headache, anorexia were noted twice, whereas bitter taste in the mouth, dizziness, arthralgia and a flu-like syndrome developed once.

Request full text

References (0)

Cited By (0)

No reference data.
No citation data.
Advertisement
Join Copernicus Academic and get access to over 12 million papers authored by 7+ million academics.
Join for free!